Bio-Techne Corp (TECH) — SEC Filings
Bio-Techne Corp (TECH) — 26 SEC filings. Latest: 10-Q (Nov 5, 2025). Includes 11 8-K, 6 10-Q, 4 SC 13G/A.
View Bio-Techne Corp on SEC EDGAR
Overview
Bio-Techne Corp (TECH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 5, 2025: BIO-TECHNE Corp reported a mixed financial performance for the quarter ended September 30, 2025. Net sales decreased slightly to $286.555 million from $289.458 million in the prior year, a 1.0% decline. Despite this, net earnings increased by 13.6% to $38.185 million, up from $33.600 million in the
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 1 bullish, 23 neutral, 2 mixed. The dominant filing sentiment for Bio-Techne Corp is neutral.
Filing Type Overview
Bio-Techne Corp (TECH) has filed 6 10-Q, 2 DEF 14A, 2 10-K, 11 8-K, 1 SC 13G, 4 SC 13G/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of TECH's 19 recent filings, 0 were flagged as high-risk, 5 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $286.555M |
| Net Income | $38.185M |
| EPS | $0.24 |
| Debt-to-Equity | 0.29 |
| Cash Position | $144.962M |
| Operating Margin | 16.6% |
| Total Assets | $2,526.148M |
| Total Debt | $300.000M |
Key Executives
- Kim Kelderman
- Dr. Amy Herr
- Dr. Roeland Nusse
- Rupert Vessey
- Dr. Judith Klimovsky
- Shane V. Bohnen
- David A. Christenson
- James M. Kohl
- Dr. Steven G. Roell
- Ms. Susan L. Roth
- Mr. Kelderman
- Mr. Kummeth
- Dr. H. Shinya Yamanaka
- Charles Kummeth
Industry Context
The life sciences and diagnostics industry is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory environment. Companies like BIO-TECHNE operate in a competitive landscape, facing pressure from both large established players and agile startups. Trends include increasing demand for personalized medicine, advanced diagnostics, and automation in research.
Top Tags
operations (5) · 10-Q (5) · financials (5) · Biotechnology (3) · biotech (3) · corporate-governance (3) · Life Sciences (2) · Diagnostics (2) · financial-reporting (2) · sec-filing (2)
Executive Compensation
From the most recent DEF 14A filing (Sep 19, 2025):
- Not Disclosed — Executive Officer: $X
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales | $286.555M | Decreased 1.0% from $289.458M in Q3 2024 |
| Net Earnings | $38.185M | Increased 13.6% from $33.600M in Q3 2024 |
| Diluted EPS | $0.24 | Increased from $0.21 in Q3 2024 |
| Net Cash from Operating Activities | $27.585M | Decreased 56.9% from $63.889M in Q3 2024 |
| Total Operating Expenses | $140.454M | Decreased from $143.030M in Q3 2024 |
| Gross Margin | $188.112M | Increased from $183.017M in Q3 2024 |
| Potential Wilson Wolf Acquisition | $1 billion | Future financial commitment based on revenue milestone |
| Spear Bio Investment | $15 million | Cost-method investment made in July 2024 |
| Foreign Currency Translation | ($2.850M) | Loss in Q3 2025 compared to $21.256M gain in Q3 2024 |
| Long-term Debt Repayments | $46.000M | Repaid in Q3 2025, up from $19.000M in Q3 2024 |
| Total Company Revenue | $1.2196B | Achieved in fiscal year 2025, demonstrating 5% organic growth. |
| Organic Growth | 5% | Achieved for the fiscal year 2025 despite a dynamic operating environment. |
| Adjusted Operating Margin | 31.6% | Achieved in fiscal year 2025, compared to 32.1% in the prior year. |
| GAAP Earnings Per Diluted Share | $0.46 | Reported in fiscal year 2025, a decrease from $1.05 in fiscal year 2024. |
| Adjusted EPS | $1.92 | Reported in fiscal year 2025, an increase from $1.77 in fiscal year 2024. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, albeit potentially fluctuating, stake in Bio-Techne Corp.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bio-Techne Corp (TECH)?
Bio-Techne Corp has 26 recent SEC filings from Jan 2024 to Nov 2025, including 11 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TECH filings?
Across 26 filings, the sentiment breakdown is: 1 bullish, 23 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Bio-Techne Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bio-Techne Corp (TECH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bio-Techne Corp?
Key financial highlights from Bio-Techne Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TECH?
The investment thesis for TECH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bio-Techne Corp?
Key executives identified across Bio-Techne Corp's filings include Kim Kelderman, Dr. Amy Herr, Dr. Roeland Nusse, Rupert Vessey, Dr. Judith Klimovsky and 9 others.
What are the main risk factors for Bio-Techne Corp stock?
Of TECH's 19 assessed filings, 0 were flagged high-risk, 5 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Bio-Techne Corp?
Recent forward-looking statements from Bio-Techne Corp include guidance on {"claim":"Vanguard will maintain a significant, albeit potentially fluctuating, stake in Bio-Techne Corp.","entity":"The.